Breaking News

Samsung Biologics Introduces S-Cellerate Platform

Offers clients an integrated and seamless drug development solution resulting in accelerated timelines.

Author Image

By: Charlie Sternberg

Associate Editor

Samsung Biologics recently introduced its proprietary technology platform, S-Cellerate, at the BioProcess International Conference (BPI 2021) to offer clients an integrated and seamless drug development solution resulting in accelerated timelines.   BPI 2021 took place both online and offline in Boston this year. Samsung Biologics attended the event on-site to closely connect with industry experts and showcase S-Cellerate at a poster session while also hosting virtual meetings to provide clients...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters